Studies of the combination of Ro 24-5913, a peptidoleukotriene antagonist, and Ro 24-4736, a PAF antagonist, in guinea pig and rat models of lung inflammation.
A F Welton et al.
Annals of the New York Academy of Sciences, 744, 274-288 (1994-11-15)
Synergism exhibited by LTD4 and PAF receptor antagonists in decreasing antigen-induced airway microvascular leakage.
M A Wasserman et al.
Advances in prostaglandin, thromboxane, and leukotriene research, 23, 271-273 (1995-01-01)
We have identified and characterized two different subclasses of binding site for the novel peptido-leukotriene (LT) antagonist, [3H]ICI 198,615, in membranes from human lung parenchyma using a receptor-ligand assay. This novel compound is representative of a new class of LT
The Journal of pharmacology and experimental therapeutics, 259(2), 751-758 (1991-11-01)
Ro 24-5913, (E)-4-[3-[2-(4-cyclobutyl-2- thiazolyl)ethenyl]phenylamino]-2,2-diethyl-4-oxobutanoic acid, has been identified as a chemically unique, potent and selective LTD4 antagonist. In vitro, Ro 24-5913 competes with [3H]LTD4 for its binding site on guinea pig lung membranes with an IC50 of 6.4 +/- 2.2
Degradation profile and reversed-phase LC method development of the antiinflammatory drug, Ro 24-5913.
N D Aggarwal et al.
Journal of pharmaceutical and biomedical analysis, 11(10), 1037-1043 (1993-10-01)
Discover Bioactive Small Molecules for Lipid Signaling Research
Questions
Reviews
★★★★★ No rating value
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
